Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DTIL NASDAQ:NLTX NASDAQ:OGI NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDTILPrecision BioSciences$4.33-2.7%$4.77$3.61▼$11.09$48.05M1.43227,629 shs194,483 shsNLTXNeoleukin Therapeutics$22.26+3.9%$18.51$2.03▼$14.36$209.20M1.1150,104 shs201,066 shsOGIOrganigram Global$1.45+1.0%$1.35$0.85▼$2.08$193.54M1.36663,380 shs151,082 shsPROKProKidney$3.42+1.6%$1.16$0.46▼$7.13$976.15M1.263.51 million shs3.40 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDTILPrecision BioSciences-4.09%-1.55%-9.18%-11.18%-56.54%NLTXNeoleukin Therapeutics+3.87%+14.15%+12.65%+95.95%-47.72%OGIOrganigram Global-3.38%0.00%+2.14%+37.50%-16.37%PROKProKidney-8.67%-9.65%+302.00%+321.25%+41.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDTILPrecision BioSciences4.1648 of 5 stars3.51.00.04.62.61.71.3NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global1.129 of 5 stars0.01.00.00.03.10.02.5PROKProKidney3.519 of 5 stars3.24.00.00.03.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDTILPrecision BioSciences 3.00Buy$47.00985.45% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/APROKProKidney 2.40Hold$6.2582.59% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, OGI, NLTX, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $9.006/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDTILPrecision BioSciences$68.70M0.70N/AN/A$6.87 per share0.63NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AOGIOrganigram Global$117.47M1.65N/AN/A$2.07 per share0.70PROKProKidney$80K12,523.90N/AN/A($3.41) per share-1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AOGIOrganigram Global-$33.39M$0.1014.45N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest DTIL, OGI, NLTX, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025OGIOrganigram Global-$0.01N/AN/AN/A$68.04 millionN/A8/8/2025Q2 2025PROKProKidney-$0.14N/AN/AN/AN/AN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09N/AN/AN/A$6.27 millionN/A5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDTILPrecision BioSciencesN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDTILPrecision BioSciences0.456.626.62NLTXNeoleukin TherapeuticsN/A15.3315.33OGIOrganigram GlobalN/A3.421.90PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDTILPrecision BioSciences37.99%NLTXNeoleukin Therapeutics52.37%OGIOrganigram Global34.63%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipDTILPrecision BioSciences4.00%NLTXNeoleukin Therapeutics1.58%OGIOrganigram Global0.09%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDTILPrecision BioSciences20011.09 million10.64 millionNo DataNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataOGIOrganigram Global860133.94 million133.82 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableDTIL, OGI, NLTX, and PROK HeadlinesRecent News About These CompaniesProKidney (NASDAQ:PROK) Trading Up 7.5% Following Analyst UpgradeJuly 16 at 2:18 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Up on Analyst UpgradeJuly 16 at 2:27 AM | americanbankingnews.comPromising clinical trial results give ProKidney share price major boostJuly 15 at 11:46 PM | journalnow.comJProKidney stock soars after FDA confirms accelerated approval pathwayJuly 15 at 11:46 PM | in.investing.comProKidney Shares Dip Following FDA Agreement on Rilparencel Approval StrategyJuly 15 at 11:46 PM | msn.comProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug TrialJuly 15 at 11:46 PM | marketwatch.comProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15 at 11:46 PM | finance.yahoo.comProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst UpgradeJuly 15 at 11:57 AM | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from BrokeragesJuly 15 at 11:53 AM | marketbeat.comProKidney Corp. Announces FDA Alignment on Accelerated Approval Pathway for Rilparencel in Chronic Kidney Disease and DiabetesJuly 15 at 7:46 AM | quiverquant.comQProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15 at 7:30 AM | globenewswire.comProKidney (NASDAQ:PROK) Shares Gap Up Following Analyst UpgradeJuly 14 at 11:55 AM | marketbeat.comGuggenheim Increases ProKidney (NASDAQ:PROK) Price Target to $7.00July 14 at 10:54 AM | marketbeat.comPromising clincial trial results give ProKidney share price major boostJuly 14 at 10:31 AM | greensboro.comGProKidney Just Set a New 52-Week High. Should You Buy, Sell, or Hold PROK Stock Here?July 14 at 10:31 AM | msn.comProKidney's (PROK) "Buy" Rating Reiterated at CitigroupJuly 12, 2025 | americanbankingnews.comProKidney (NASDAQ:PROK) Sees Large Volume Increase Following Analyst UpgradeJuly 12, 2025 | americanbankingnews.comProKidney (PROK) Gets a Sell from Bank of America SecuritiesJuly 11, 2025 | theglobeandmail.comProKidney (NASDAQ:PROK) Shares Gap Down - Should You Sell?July 11, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Sees Large Volume Increase After Analyst UpgradeJuly 10, 2025 | marketbeat.comDarin J. Weber Sells 103,480 Shares of ProKidney Corp. (NASDAQ:PROK) StockJuly 10, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractWhy Occidental's Price Dip Signals a Buying OpportunityBy Jeffrey Neal Johnson | July 3, 2025View Why Occidental's Price Dip Signals a Buying OpportunityDTIL, OGI, NLTX, and PROK Company DescriptionsPrecision BioSciences NASDAQ:DTIL$4.33 -0.12 (-2.70%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Neoleukin Therapeutics NASDAQ:NLTX$22.26 +0.83 (+3.87%) As of 07/14/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Organigram Global NASDAQ:OGI$1.44 +0.02 (+1.05%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.ProKidney NASDAQ:PROK$3.42 +0.05 (+1.57%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
